Document is current

Article History

Received: 8 March 2023

Accepted: 25 July 2023

First Online: 3 October 2023

Declarations

:

: Anika Wranke, Benjamin Heidrich, Katharina Luise Hupa-Breier, Janina Kirschner, and Birgit Bremer declare that they have no conflict of interest. Heiner Wedemeyer serves as clinical trials principal investigator for Abbvie, Altimmune, BMS, Gilead, Janssen, Merck/MSD, MYR GmbH, Novartis, and Vir Biotechnology, has research grants from Abbvie, Biotest, Gilead, Merck/MSD, and Roche, and advises or is on the speakers’ bureau for AbbVie, Aligos, Altimmune, Biotest, BMS, BTG, Dicerna, Enanta, Gilead, Janssen, Merck/MSD, MYR GmbH, Roche, and Vir Biotechnology. Markus Cornberg received honoraria for lectures or consulting from AbbVie, AiCuris, Falk, Gilead, GlaxoSmithKline (GSK), Janssen, Merck/MSD, Novartis, Roche, Swedish Orphan Biovitrum (SOBI). Katja Deterding received lecture fees and is on the advisory board for Gilead.

: The study was approved by the local ethics committee of Hannover Medical School (Hannover, Germany) and performed in accordance with the ethical standards as laid down in the Helsinki Declaration of 1975, as revised in 2008.

: Informed consent was not required from patients included in the study, as all patient information was de-identified and because of the retrospective nature of this study.

: All authors approved the manuscript for publication.